At the recent American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, researchers reported that treatment with benralizumab (Fasenra) was noninferior to mepolizumab (Nucala) for ...

Please provide your email address to receive an email when new articles are posted on . Systemic corticosteroid use decreased with mepolizumab treatment. Mean daily oral corticosteroid use fell by 18% ...

Granulomatosis with polyangiitis (GPA) is a rare condition where the blood vessels become inflamed GRANULOMATOSIS with polyangiitis is a serious condition that can have life-threatening consequences ...

Please provide your email address to receive an email when new articles are posted on . Safety and tolerability were consistent with benralizumab’s known profile. Benralizumab is currently approved as ...

Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on ...

NS-229 is currently being evaluated in a phase 2 trial in patients with eosinophilic granulomatosis with polyangiitis. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

Amgen Inc.’s AMGN Japanese partner Kissei Pharmaceutical Co., Ltd. said it has started information-sharing activities in ...

Antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis is a severe condition encompassing two major syndromes: granulomatosis with polyangiitis (formerly known as Wegener's granulomatosis) ...

A patient with MPA may suffer general symptoms or symptoms localized to the kidney, lungs, digestive tract, nerves, skin or heart. The patient may show initial symptoms of fever, muscle pains and ...

Relapses in patients with granulomatosis with polyangiitis (GPA) largely mirrored the initial disease pattern, most often affecting the ENT, lungs, or kidneys, with serious features recurring.